You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameNabilone
Accession NumberDB00486  (APRD01127)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionNabilone is a synthetic cannabinoid with therapeutic use as an antiemetic and as an adjunct analgesic for neuropathic pain. It is a synthetic cannabinoid, which mimics the main ingredient of marijuana (THC) but it has more predictable side effects and causes no or minimal euphoria. Nabilone is not derived from the cannabis plant as is dronabinol. In Canada, the United States, the United Kingdom and Mexico, nabilone is marketed as Cesamet. It was approved in 1985 by the United States FDA for treatment of chemotherapy-induced nausea and vomiting that has not responded to conventional antiemetics. Though it was approved by the FDA in 1985, the drug only began marketing in the United States in 2006. It is also approved for use in treatment of anorexia and weight loss in patients with AIDS. Although it doesn't have the official indication (except in Mexico), nabilone is widely used as an adjunct therapy for chronic pain management. Numerous trials and case studies have demonstrate various benefits for condition such as fibromyalgia and multiple scerosis. Nabilone is a racemate consisting of the (S,S) and the (R,R) isomers ("trans").
Structure
Thumb
Synonyms
Cesamet
Nabilon
Nabilona
Nabilone
Nabilonum
External Identifiers
  • Cpd 109514
  • LY 109 514
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Act NabiloneCapsule0.5 mgOralActavis Pharma Company2012-10-02Not applicableCanada
Act NabiloneCapsule1 mgOralActavis Pharma Company2012-10-02Not applicableCanada
CesametCapsule1 mg/1OralMeda Pharmaceuticals Inc.2010-03-01Not applicableUs
CesametCapsule0.25 mgOralValeant Canada Lp Valeant Canada S.E.C.2008-09-12Not applicableCanada
CesametCapsule1 mg/1OralValeant Pharmaceuticals North America2009-11-01Not applicableUs
CesametCapsule1 mgOralValeant Canada Lp Valeant Canada S.E.C.1982-12-31Not applicableCanada
CesametCapsule0.5 mgOralValeant Canada Lp Valeant Canada S.E.C.2004-09-16Not applicableCanada
PMS-nabiloneCapsule0.25 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-nabiloneCapsule0.5 mgOralPharmascience Inc2012-03-26Not applicableCanada
PMS-nabiloneCapsule1.0 mgOralPharmascience Inc2012-03-26Not applicableCanada
Ran-nabiloneCapsule1 mgOralRanbaxy Pharmaceuticals Canada Inc.2012-03-27Not applicableCanada
Ran-nabiloneCapsule0.25 mgOralRanbaxy Pharmaceuticals Canada Inc.2012-03-27Not applicableCanada
Ran-nabiloneCapsule0.5 mgOralRanbaxy Pharmaceuticals Canada Inc.2012-03-27Not applicableCanada
Teva-nabiloneCapsule1.0 mgOralTeva Canada Limited2012-05-23Not applicableCanada
Teva-nabiloneCapsule0.25 mgOralTeva Canada Limited2013-05-27Not applicableCanada
Teva-nabiloneCapsule0.5 mgOralTeva Canada Limited2012-05-23Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-nabiloneCapsule0.25 mgOralApotex IncNot applicableNot applicableCanada
Apo-nabiloneCapsule0.5 mgOralApotex IncNot applicableNot applicableCanada
Apo-nabiloneCapsule1 mgOralApotex IncNot applicableNot applicableCanada
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
NabiloneMeda
Brand mixturesNot Available
SaltsNot Available
Categories
UNII2N4O9L084N
CAS number51022-71-0
WeightAverage: 372.5408
Monoisotopic: 372.266445018
Chemical FormulaC24H36O3
InChI KeyGECBBEABIDMGGL-RTBURBONSA-N
InChI
InChI=1S/C24H36O3/c1-6-7-8-9-12-23(2,3)16-13-20(26)22-18-15-17(25)10-11-19(18)24(4,5)27-21(22)14-16/h13-14,18-19,26H,6-12,15H2,1-5H3/t18-,19-/m1/s1
IUPAC Name
(6aR,10aR)-1-hydroxy-6,6-dimethyl-3-(2-methyloctan-2-yl)-6H,6aH,7H,8H,9H,10H,10aH-benzo[c]isochromen-9-one
SMILES
[H][C@@]12CC(=O)CC[C@@]1([H])C(C)(C)OC1=CC(=CC(O)=C21)C(C)(C)CCCCCC
Pharmacology
IndicationUsed for the control of nausea and vomiting, caused by chemotherapeutic agents used in the treatment of cancer, in patients who have failed to respond adequately to conventional antiemetic treatments.
Structured Indications
PharmacodynamicsNabilone is a cannabinoid with therapeutic uses. It is an analog of dronabinol (also known as tetrahydrocannabinol or THC), the psychoactive ingredient in cannabis. It is reserved for use in individuals who do not respond to the more commonly used anti-emetics. This is mainly because cannabinoids have potential adverse effects similar to that of cannabis and may cause changes in mood and behaviour.
Mechanism of actionThe mode of action of nabilone has been studied in cats and dogs. Although its anti-emetic action is not yet fully understood, it is apparent that there are a number of points in the control systems of the body at which Nabilone could block the emetic mechanism. It is likely that nabilone exerts its actions via binding to the cannabinoid receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Cannabinoid receptor 2Proteinyes
partial agonist
HumanP34972 details
Cannabinoid receptor 1Proteinyes
partial agonist
HumanP21554 details
Related Articles
AbsorptionRapidly absorbed from the gastrointestinal tract following oral administration.
Volume of distribution
  • 12.5 L/kg
Protein bindingNot Available
Metabolism

Hepatic. Two metabolic pathways have been suggested. The major pathway probably involves the direct oxidation of Nabilone to produce hydroxylic and carboxylic analogues. These compounds are thought to account for the remaining plasma radioactivity when carbinol metabolites have been extracted.

Route of eliminationThe route and rate of the elimination of nabilone and its metabolites are similar to those observed with other cannabinoids, including delta-9-THC (dronabinol). Therefore, it appears that the major excretory pathway is the biliary system.
Half life2 hours, with metabolites around 35 hours.
ClearanceNot Available
ToxicitySymptoms of overdose include difficulty in breathing, hallucinations, mental changes (severe), nervousness or anxiety (severe). Monkeys treated with Nabilone at doses as high as 2mg/kg/day for a year experienced no significant adverse events. This result contrasts with the finding in a planned 1-year dog study that was prematurely terminated because of deaths associated with convulsions in dogs receiving as little as 0.5mg/kg/day. The earliest deaths, however, occurred at 56 days in dogs receiving 2mg/kg/day. The unusual vulnerability of the dog is not understood; it is hypothesised, however, that the explanation lies in the fact that the dog differs markedly from other species (including humans) in its metabolism of Nabilone.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneNabilone may increase the central nervous system depressant (CNS depressant) activities of 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
AcebutololNabilone may increase the tachycardic activities of Acebutolol.Approved
AcepromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Nabilone is combined with Acetazolamide.Approved, Vet Approved
AclidiniumAclidinium may increase the tachycardic activities of Nabilone.Approved
adipiplonNabilone may increase the central nervous system depressant (CNS depressant) activities of adipiplon.Investigational
AgomelatineNabilone may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Nabilone.Approved
AlfaxaloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Nabilone.Approved, Investigational
AlphacetylmethadolNabilone may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlprazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Nabilone.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Nabilone.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Nabilone.Approved, Investigational
AmisulprideNabilone may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
AmitriptylineNabilone may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Nabilone.Approved
AmobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmoxapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmperozideNabilone may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
AmphetamineNabilone may increase the tachycardic activities of Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Nabilone.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Nabilone.Approved
Anisotropine MethylbromideAnisotropine Methylbromide may increase the tachycardic activities of Nabilone.Approved
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Nabilone.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Nabilone.Approved
AripiprazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nabilone.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Nabilone.Approved, Investigational
ArticaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AtenololThe risk or severity of adverse effects can be increased when Atenolol is combined with Nabilone.Approved
Atracurium besylateAtracurium besylate may increase the tachycardic activities of Nabilone.Approved
AtropineAtropine may increase the tachycardic activities of Nabilone.Approved, Vet Approved
AzaperoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Vet Approved
AzelastineNabilone may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Nabilone.Approved
BaclofenNabilone may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Nabilone.Experimental
BarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Nabilone.Approved
BenactyzineBenactyzine may increase the tachycardic activities of Nabilone.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Nabilone.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Nabilone.Approved
BenperidolNabilone may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Investigational
BenzatropineBenzatropine may increase the tachycardic activities of Nabilone.Approved
BenzocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
BenzphetamineNabilone may increase the tachycardic activities of Benzphetamine.Approved, Illicit
Benzyl alcoholNabilone may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Nabilone.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Betaxolol is combined with Nabilone.Approved
BiperidenBiperiden may increase the tachycardic activities of Nabilone.Approved
BisoprololThe risk or severity of adverse effects can be increased when Bisoprolol is combined with Nabilone.Approved
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Nabilone.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Bretylium is combined with Nabilone.Approved
BrexpiprazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
BrimonidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
BromazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Nabilone.Approved, Investigational
BrompheniramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Withdrawn
BucindololNabilone may increase the tachycardic activities of Bucindolol.Investigational
BumetanideThe risk or severity of adverse effects can be increased when Bumetanide is combined with Nabilone.Approved
BupivacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BuprenorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeNabilone may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenNabilone may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
ButethalNabilone may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButorphanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Nabilone.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Nabilone.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Nabilone.Approved
CarbamazepineNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Nabilone.Approved
CarbinoxamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarfentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Vet Approved
CarisoprodolNabilone may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CarteololThe risk or severity of adverse effects can be increased when Carteolol is combined with Nabilone.Approved
CarvedilolThe risk or severity of adverse effects can be increased when Carvedilol is combined with Nabilone.Approved, Investigational
CeliprololNabilone may increase the tachycardic activities of Celiprolol.Approved, Investigational
CetirizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydrateNabilone may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit
ChlormezanoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Withdrawn
ChloroprocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Chlorothiazide is combined with Nabilone.Approved, Vet Approved
ChlorphenamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorphenoxamineChlorphenoxamine may increase the tachycardic activities of Nabilone.Withdrawn
ChlorphentermineNabilone may increase the tachycardic activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Chlorthalidone is combined with Nabilone.Approved
ChlorzoxazoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Nabilone.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Nabilone.Approved
CinchocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Nabilone is combined with Citalopram.Approved
ClemastineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved
ClenbuterolNabilone may increase the tachycardic activities of Clenbuterol.Approved, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Nabilone.Approved
ClidiniumNabilone may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClobazamNabilone may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Nabilone.Approved, Investigational
clomethiazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
ClonazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
ClorazepateNabilone may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
ClozapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeineNabilone may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Nabilone.Approved, Investigational
CyclizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyclopentolateCyclopentolate may increase the tachycardic activities of Nabilone.Approved
CyproheptadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DantroleneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Nabilone.Approved
DapiprazoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Nabilone is combined with Dapoxetine.Investigational
DarifenacinDarifenacin may increase the tachycardic activities of Nabilone.Approved, Investigational
deramciclaneNabilone may increase the central nervous system depressant (CNS depressant) activities of deramciclane.Investigational
DesfluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
DesloratadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Nabilone is combined with Desvenlafaxine.Approved
DetomidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DexbrompheniramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexetimideDexetimide may increase the tachycardic activities of Nabilone.Withdrawn
DexmedetomidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DextromoramideNabilone may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneNabilone may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved
DiazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Nabilone.Approved
DicyclomineDicyclomine may increase the tachycardic activities of Nabilone.Approved
DifenoxinNabilone may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DihydrocodeineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DiltiazemThe risk or severity of adverse effects can be increased when Diltiazem is combined with Nabilone.Approved
DimenhydrinateNabilone may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Nabilone.Approved
DiphenhydramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
DiphenoxylateNabilone may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Nabilone.Approved
DobutamineNabilone may increase the tachycardic activities of Dobutamine.Approved
DopamineNabilone may increase the tachycardic activities of Dopamine.Approved
DoramectinNabilone may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nabilone.Approved
DoxepinNabilone may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
DoxylamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Vet Approved
DPDPENabilone may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Vet Approved
DrotebanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DuloxetineNabilone may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineNabilone may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgonineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERNabilone may increase the central nervous system depressant (CNS depressant) activities of ECGONINE METHYL ESTER.Experimental
EcopipamNabilone may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzNabilone may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Efonidipine is combined with Nabilone.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Nabilone.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Nabilone.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Nabilone.Approved
EnfluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Vet Approved
EntacaponeNabilone may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
EphedrineNabilone may increase the tachycardic activities of Ephedrine.Approved
EpinephrineNabilone may increase the tachycardic activities of Epinephrine.Approved, Vet Approved
EplerenoneThe risk or severity of adverse effects can be increased when Eplerenone is combined with Nabilone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Nabilone.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Nabilone.Approved
EscitalopramThe risk or severity of adverse effects can be increased when Nabilone is combined with Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Nabilone.Approved
EstazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EszopicloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Etacrynic acid is combined with Nabilone.Approved
EthanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthopropazineEthopropazine may increase the tachycardic activities of Nabilone.Approved
EthosuximideNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl carbamateNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl loflazepateNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
EtidocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
EtifoxineNabilone may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Withdrawn
EtilefrineNabilone may increase the tachycardic activities of Etilefrine.Withdrawn
EtizolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtomidateNabilone may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Nabilone is combined with Etoperidone.Approved
EtorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EzogabineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved
FelbamateNabilone may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Nabilone.Approved, Investigational
FencamfamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Nabilone.Approved
FenoterolNabilone may increase the tachycardic activities of Fenoterol.Approved
FentanylNabilone may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineFesoterodine may increase the tachycardic activities of Nabilone.Approved
FexofenadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Nabilone.Approved
FlibanserinNabilone may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
FludiazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FlunarizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Nabilone is combined with Fluoxetine.Approved, Vet Approved
FlupentixolNabilone may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Withdrawn
FluphenazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit
FluspirileneNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved
Fluticasone PropionateNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluticasone Propionate.Approved
FluvoxamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Nabilone.Approved
FosphenytoinNabilone may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.Approved
FospropofolNabilone may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Nabilone.Approved, Vet Approved
GabapentinNabilone may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
gabapentin enacarbilNabilone may increase the central nervous system depressant (CNS depressant) activities of gabapentin enacarbil.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the tachycardic activities of Nabilone.Approved
Gamma Hydroxybutyric AcidNabilone may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeNabilone may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GlutethimideNabilone may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GlycopyrroniumGlycopyrronium may increase the tachycardic activities of Nabilone.Approved, Investigational, Vet Approved
GuanfacineNabilone may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
HalazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HaloperidolNabilone may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HalothaneNabilone may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HeroinNabilone may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit
HexamethoniumHexamethonium may increase the tachycardic activities of Nabilone.Experimental
HexobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HomatropineHomatropine may increase the tachycardic activities of Nabilone.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Nabilone.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Nabilone.Approved, Vet Approved
HydrocodoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Nabilone.Approved
HydromorphoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
Hydroxyamphetamine hydrobromideNabilone may increase the tachycardic activities of Hydroxyamphetamine hydrobromide.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved
HyoscyamineHyoscyamine may increase the tachycardic activities of Nabilone.Approved
IloperidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Nabilone.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Nabilone.Investigational
ImipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Nabilone is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Indapamide is combined with Nabilone.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Nabilone.Withdrawn
Ipratropium bromideIpratropium bromide may increase the tachycardic activities of Nabilone.Approved
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Nabilone.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Nabilone.Approved
IsofluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
IsoprenalineNabilone may increase the tachycardic activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Nabilone.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Nabilone.Approved
IsoxsuprineNabilone may increase the tachycardic activities of Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Isradipine is combined with Nabilone.Approved
KetamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved
LabetalolNabilone may increase the tachycardic activities of Labetalol.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Nabilone.Approved
LamotrigineNabilone may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Nabilone.Approved, Investigational
LevetiracetamNabilone may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Levobunolol is combined with Nabilone.Approved
LevobupivacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved
LevocabastineNabilone may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved
LevocetirizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaNabilone may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
Levomethadyl AcetateNabilone may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Nabilone is combined with Levomilnacipran.Approved
LevorphanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Nabilone.Approved, Investigational
LidocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Nabilone.Approved, Investigational
LithiumNabilone may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
LofentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Nabilone.Approved, Investigational
LoratadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
LorazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Nabilone.Approved
LoxapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
Lu AA21004Nabilone may increase the central nervous system depressant (CNS depressant) activities of Lu AA21004.Investigational
LurasidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Nabilone.Approved, Investigational
MaprotilineNabilone may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
MecamylamineMecamylamine may increase the tachycardic activities of Nabilone.Approved
MeclizineNabilone may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedetomidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
MelatoninNabilone may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved
MephentermineNabilone may increase the tachycardic activities of Mephentermine.Approved
MepivacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamateNabilone may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MesoridazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved
MetaraminolNabilone may increase the tachycardic activities of Metaraminol.Approved, Investigational
MetaxaloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MethadoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateNabilone may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethamphetamineNabilone may increase the tachycardic activities of Methamphetamine.Approved, Illicit
MethanthelineMethantheline may increase the tachycardic activities of Nabilone.Approved
MethapyrileneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Nabilone.Approved
MethocarbamolNabilone may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethotrimeprazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineNabilone may increase the tachycardic activities of Methoxamine.Approved
MethoxyfluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Vet Approved
MethsuximideNabilone may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nabilone.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Methyldopa is combined with Nabilone.Approved
MethylphenobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MetipranololThe risk or severity of adverse effects can be increased when Metipranolol is combined with Nabilone.Approved
MetixeneMetixene may increase the tachycardic activities of Nabilone.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Metolazone is combined with Nabilone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nabilone.Approved, Investigational
MetyrosineNabilone may increase the sedative activities of Metyrosine.Approved
MidazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MidodrineNabilone may increase the tachycardic activities of Midodrine.Approved
MilnacipranThe risk or severity of adverse effects can be increased when Nabilone is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Nabilone.Approved
MirtazapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Nabilone.Approved
MolindoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MorphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Nabilone.Approved
N-butylscopolammonium bromideN-butylscopolammonium bromide may increase the tachycardic activities of Nabilone.Vet Approved
NadololThe risk or severity of adverse effects can be increased when Nadolol is combined with Nabilone.Approved
NalbuphineNabilone may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
NebivololThe risk or severity of adverse effects can be increased when Nebivolol is combined with Nabilone.Approved, Investigational
NefazodoneThe risk or severity of adverse effects can be increased when Nabilone is combined with Nefazodone.Approved, Withdrawn
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Nabilone.Approved, Investigational
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Nabilone.Approved
NicorandilNicorandil may increase the hypotensive activities of Nabilone.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Nabilone.Approved
NilvadipineThe risk or severity of adverse effects can be increased when Nabilone is combined with Nilvadipine.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Nabilone.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Nabilone.Approved
NitrazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitrendipine.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nabilone is combined with Nitric Oxide.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Nabilone.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Nabilone.Approved
Nitrous oxideNabilone may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NorepinephrineNabilone may increase the tachycardic activities of Norepinephrine.Approved
NormethadoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylineNabilone may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
NVA237NVA237 may increase the tachycardic activities of Nabilone.Investigational
NylidrinNabilone may increase the tachycardic activities of Nylidrin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Nabilone is combined with Obinutuzumab.Approved
OlanzapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Nabilone.Approved, Investigational
OlopatadineNabilone may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OndansetronNabilone may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpiumNabilone may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrciprenalineNabilone may increase the tachycardic activities of Orciprenaline.Approved
OrphenadrineNabilone may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantNabilone may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OxazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxetacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxetacaine.Investigational
OxprenololNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
OxybuprocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved
OxybutyninOxybutynin may increase the tachycardic activities of Nabilone.Approved, Investigational
OxycodoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineNabilone may increase the tachycardic activities of Oxymetazoline.Approved
OxymorphoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumOxyphenonium may increase the tachycardic activities of Nabilone.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Nabilone is combined with Paclitaxel.Approved, Vet Approved
PaliperidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PancuroniumPancuronium may increase the tachycardic activities of Nabilone.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Nabilone.Approved
ParaldehydeNabilone may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Nabilone is combined with Paroxetine.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Penbutolol is combined with Nabilone.Approved, Investigational
PentazocineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
PentoliniumPentolinium may increase the tachycardic activities of Nabilone.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved
PerazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Nabilone.Approved
PerospironeNabilone may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenelzineThe risk or severity of adverse effects can be increased when Nabilone is combined with Phenelzine.Approved
PhenmetrazineNabilone may increase the tachycardic activities of Phenmetrazine.Approved, Illicit
PhenobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Nabilone is combined with Phenoxybenzamine.Approved
PhenoxyethanolNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhentermineNabilone may increase the tachycardic activities of Phentermine.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Nabilone is combined with Phentolamine.Approved
PhenylephrineNabilone may increase the tachycardic activities of Phenylephrine.Approved
PhenylpropanolamineNabilone may increase the tachycardic activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinNabilone may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.Approved, Vet Approved
PimozideNabilone may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PindololThe risk or severity of adverse effects can be increased when Pindolol is combined with Nabilone.Approved
PipamperoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved
PipecuroniumPipecuronium may increase the tachycardic activities of Nabilone.Approved
PipotiazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved
PirenzepinePirenzepine may increase the tachycardic activities of Nabilone.Approved
PiritramideNabilone may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Investigational
PizotifenNabilone may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
PomalidomideNabilone may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PramipexoleNabilone may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PrazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Nabilone.Approved
PregabalinNabilone may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PregnanoloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Pregnanolone.Investigational
PrilocaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Primidone.Approved, Vet Approved
ProcaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
ProcaterolNabilone may increase the tachycardic activities of Procaterol.Approved
ProchlorperazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
ProcyclidineProcyclidine may increase the tachycardic activities of Nabilone.Approved
PromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
PropanthelinePropantheline may increase the tachycardic activities of Nabilone.Approved
ProparacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropiverinePropiverine may increase the tachycardic activities of Nabilone.Investigational
PropofolNabilone may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
PropranololThe risk or severity of adverse effects can be increased when Propranolol is combined with Nabilone.Approved, Investigational
ProtriptylineNabilone may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
PSD502Nabilone may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
PseudoephedrineNabilone may increase the tachycardic activities of Pseudoephedrine.Approved
QuazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapineNabilone may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Nabilone.Approved, Investigational
QuinidineQuinidine may increase the tachycardic activities of Nabilone.Approved
RacepinephrineNabilone may increase the tachycardic activities of Racepinephrine.Approved
RacloprideNabilone may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RamelteonNabilone may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Nabilone.Approved
RasagilineThe risk or severity of adverse effects can be increased when Nabilone is combined with Rasagiline.Approved
RemifentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemoxiprideNabilone may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
ReserpineNabilone may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Nabilone.Approved
RisperidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
RitanserinNabilone may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RitodrineNabilone may increase the tachycardic activities of Ritodrine.Approved
RomifidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopiniroleNabilone may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
RotigotineNabilone may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Nabilone.Approved
S-EthylisothioureaNabilone may increase the central nervous system depressant (CNS depressant) activities of S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Nabilone is combined with Sacubitril.Approved
Sage 547Nabilone may increase the central nervous system depressant (CNS depressant) activities of Sage 547.Investigational
ScopolamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
Scopolamine butylbromideScopolamine butylbromide may increase the tachycardic activities of Nabilone.Approved
SecobarbitalNabilone may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Nabilone is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleNabilone may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Nabilone is combined with Sertraline.Approved
SevofluraneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Nabilone is combined with Sodium Nitrite.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved
SolifenacinSolifenacin may increase the tachycardic activities of Nabilone.Approved
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Nabilone.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Nabilone.Approved
StiripentolNabilone may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Nabilone is combined with Streptokinase.Approved
SufentanilNabilone may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulpirideNabilone may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved
SuvorexantNabilone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
SynephrineNabilone may increase the tachycardic activities of Synephrine.Experimental
TamsulosinThe risk or severity of adverse effects can be increased when Nabilone is combined with Tamsulosin.Approved, Investigational
TandospironeNabilone may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved
TasimelteonNabilone may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Nabilone.Approved, Investigational
TemazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Nabilone.Approved
TerbutalineNabilone may increase the tachycardic activities of Terbutaline.Approved
TetrabenazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
TetracaineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetrodotoxinNabilone may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
TetryzolineNabilone may increase the tachycardic activities of Tetryzoline.Approved
ThalidomideNabilone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioridazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved
ThiothixeneNabilone may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TiagabineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
TiaprideNabilone may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Investigational
TiletamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TimololThe risk or severity of adverse effects can be increased when Timolol is combined with Nabilone.Approved
TiotropiumTiotropium may increase the tachycardic activities of Nabilone.Approved
TizanidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
TolazolineThe risk or severity of adverse effects can be increased when Nabilone is combined with Tolazoline.Approved, Vet Approved
TolcaponeNabilone may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the tachycardic activities of Nabilone.Approved, Investigational
TopiramateNabilone may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Nabilone.Approved
TramadolNabilone may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Nabilone.Approved
Trans-2-PhenylcyclopropylamineNabilone may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineNabilone may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
TrazodoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Nabilone is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Nabilone.Approved
TriazolamNabilone may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
TrifluoperazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TriflupromazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrihexyphenidylTrihexyphenidyl may increase the tachycardic activities of Nabilone.Approved
TrimethaphanTrimethaphan may increase the tachycardic activities of Nabilone.Approved
TrimipramineNabilone may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidineNabilone may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
TropicamideTropicamide may increase the tachycardic activities of Nabilone.Approved
TrospiumTrospium may increase the tachycardic activities of Nabilone.Approved
TubocurarineTubocurarine may increase the tachycardic activities of Nabilone.Approved
TyramineNabilone may increase the tachycardic activities of Tyramine.Investigational, Nutraceutical
Uc1010Nabilone may increase the central nervous system depressant (CNS depressant) activities of Uc1010.Investigational
UmeclidiniumUmeclidinium may increase the tachycardic activities of Nabilone.Approved
Valproic AcidNabilone may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Nabilone.Approved, Investigational
VecuroniumVecuronium may increase the tachycardic activities of Nabilone.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Nabilone is combined with Venlafaxine.Approved
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Nabilone.Approved
VigabatrinNabilone may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
VortioxetineNabilone may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
XylazineNabilone may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Nabilone can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonNabilone may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZiconotideNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Nabilone is combined with Zimelidine.Withdrawn
ZiprasidoneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZolazepamNabilone may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
ZolpidemNabilone may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideNabilone may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopicloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepineNabilone may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved
ZuclopenthixolNabilone may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take without regard to meals. Avoid alcohol.
References
Synthesis ReferenceNot Available
General References
  1. Cunningham D, Bradley CJ, Forrest GJ, Hutcheon AW, Adams L, Sneddon M, Harding M, Kerr DJ, Soukop M, Kaye SB: A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues. Eur J Cancer Clin Oncol. 1988 Apr;24(4):685-9. [PubMed:2838294 ]
  2. Niiranen A, Mattson K: Antiemetic efficacy of nabilone and dexamethasone: a randomized study of patients with lung cancer receiving chemotherapy. Am J Clin Oncol. 1987 Aug;10(4):325-9. [PubMed:3039831 ]
  3. Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC, Furnas B, Williams SD, Leigh SA, Dorr RT, Moon TE: Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. N Engl J Med. 1979 Jun 7;300(23):1295-7. [PubMed:375088 ]
  4. Einhorn LH, Nagy C, Furnas B, Williams SD: Nabilone: an effective antiemetic in patients receiving cancer chemotherapy. J Clin Pharmacol. 1981 Aug-Sep;21(8-9 Suppl):64S-69S. [PubMed:6271844 ]
External Links
ATC CodesA04AD11
AHFS Codes
  • 56:22.92
PDB EntriesNot Available
FDA labelDownload (94.9 KB)
MSDSNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9954
Blood Brain Barrier+0.9575
Caco-2 permeable+0.7787
P-glycoprotein substrateSubstrate0.8103
P-glycoprotein inhibitor INon-inhibitor0.7926
P-glycoprotein inhibitor IIInhibitor0.6054
Renal organic cation transporterNon-inhibitor0.836
CYP450 2C9 substrateNon-substrate0.7385
CYP450 2D6 substrateNon-substrate0.8433
CYP450 3A4 substrateSubstrate0.6842
CYP450 1A2 substrateNon-inhibitor0.6601
CYP450 2C9 inhibitorNon-inhibitor0.714
CYP450 2D6 inhibitorNon-inhibitor0.9059
CYP450 2C19 inhibitorNon-inhibitor0.6521
CYP450 3A4 inhibitorNon-inhibitor0.8654
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7642
Ames testNon AMES toxic0.8337
CarcinogenicityNon-carcinogens0.8598
BiodegradationNot ready biodegradable0.9948
Rat acute toxicity2.5397 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9159
hERG inhibition (predictor II)Non-inhibitor0.7654
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Meda pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral0.25 mg
CapsuleOral0.5 mg
CapsuleOral1 mg/1
CapsuleOral1 mg
CapsuleOral1.0 mg
Prices
Unit descriptionCostUnit
Cesamet 1 mg capsule13.99USD capsule
Cesamet 0.5 mg Capsule3.49USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP6.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.000493 mg/mLALOGPS
logP7.5ALOGPS
logP6.36ChemAxon
logS-5.9ALOGPS
pKa (Strongest Acidic)9.33ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity110.2 m3·mol-1ChemAxon
Polarizability44.91 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthopyranones. These are compounds containing a naphthopyran skeleton where a ring carbon bears a carboxylic acid group. Naphthtopyran is made up of the pyran ring fused to a naphthalene ring system.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassNaphthopyrans
Sub ClassNaphthopyranones
Direct ParentNaphthopyranones
Alternative Parents
Substituents
  • Naphthopyranone
  • 2,2-dimethyl-1-benzopyran
  • 1-benzopyran
  • Benzopyran
  • Chromane
  • Cyclohexanone
  • Alkyl aryl ether
  • Benzenoid
  • Cyclic ketone
  • Ketone
  • Oxacycle
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Cannabinoid receptor activity
Specific Function:
Heterotrimeric G protein-coupled receptor for endocannabinoid 2-arachidonoylglycerol mediating inhibition of adenylate cyclase. May function in inflammatory response, nociceptive transmission and bone homeostasis.
Gene Name:
CNR2
Uniprot ID:
P34972
Molecular Weight:
39680.275 Da
References
  1. Conti S, Costa B, Colleoni M, Parolaro D, Giagnoni G: Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br J Pharmacol. 2002 Jan;135(1):181-7. [PubMed:11786493 ]
  2. Mendizabal VE, Adler-Graschinsky E: Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol. 2007 Jun;151(4):427-40. Epub 2007 Apr 23. [PubMed:17450170 ]
  3. Davis M, Maida V, Daeninck P, Pergolizzi J: The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer. 2007 Jan;15(1):63-71. Epub 2006 Dec 1. [PubMed:17139494 ]
  4. Kraft B, Kress HG: [Cannabinoids and the immune system. Of men, mice and cells]. Schmerz. 2004 Jun;18(3):203-10. [PubMed:15221424 ]
  5. Darmani NA: The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol. 2001 Oct 26;430(1):49-58. [PubMed:11698062 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Drug binding
Specific Function:
Involved in cannabinoid-induced CNS effects. Acts by inhibiting adenylate cyclase. Could be a receptor for anandamide. Inhibits L-type Ca(2+) channel current. Isoform 2 and isoform 3 have altered ligand binding.
Gene Name:
CNR1
Uniprot ID:
P21554
Molecular Weight:
52857.365 Da
References
  1. Davis M, Maida V, Daeninck P, Pergolizzi J: The emerging role of cannabinoid neuromodulators in symptom management. Support Care Cancer. 2007 Jan;15(1):63-71. Epub 2006 Dec 1. [PubMed:17139494 ]
  2. Darmani NA: The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol. 2001 Oct 26;430(1):49-58. [PubMed:11698062 ]
  3. Hirst RA, Almond SL, Lambert DG: Characterisation of the rat cerebella CB1 receptor using SR141716A, a central cannabinoid receptor antagonist. Neurosci Lett. 1996 Dec 13;220(2):101-4. [PubMed:8981483 ]
  4. Pertwee RG: Cannabis and cannabinoids: pharmacology and rationale for clinical use. Forsch Komplementarmed. 1999 Oct;6 Suppl 3:12-5. [PubMed:10575283 ]
  5. Pertwee RG, Fernando SR: Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder. Br J Pharmacol. 1996 Aug;118(8):2053-8. [PubMed:8864542 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23